ClinicalTrials.Veeva

Menu

A Study on Higher-dose Oseltamivir Treatment's Impact on Viral Clearance and Clinical Recovery in Adults Hospitalized With Influenza

The Chinese University of Hong Kong logo

The Chinese University of Hong Kong

Status and phase

Completed
Phase 4

Conditions

Influenza
Respiratory Tract Infections

Treatments

Drug: Oseltamivir

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT01052961
CUHK 7010015, MV22926

Details and patient eligibility

About

Adult patients hospitalized with influenza have higher viral loads and more severe illnesses. Thus more aggressive treatment approaches (e.g. higher dose oseltamivir) have been suggested to treat patients suffering from severe influenza infection.

The investigators plan to investigate the impact of higher-dose oseltamivir (150 mg b.d.) treatment on viral clearance and clinical recovery in adult patients hospitalized for severe influenza. Such information may lead to optimization of the management strategy used for these patients.

Full description

  • The investigators plan to study the impact of higher-dose oseltamivir (150 mg b.d.) treatment on rate of viral load decline and RNA negativity (in nasal and throat swabs, assessed by quantitative RT-PCR assay) and time to clinical recovery in adult patients hospitalized for severe influenza.
  • Patients who received intervention (oseltamivir 150 mg b.d. for 5 days) will be compared to those in the non-intervention arm (patients may receive oseltamivir treatment at 75 mg b.d. for 5 days, decided by their managing physicians) in the two respective study sites. Viral load changes and viral clearance will be compared. Clinical progress and time to symptom recovery will be reported. The protocol will be crossed-over to the other site at a defined time frame.
  • oseltamivir 150 mg b.d. has been shown to be safe and well-tolerated in earlier clinical trials
  • higher-dose treatment has been suggested by health authorities (e.g. WHO) to treat severe influenza infection/pneumonia.

Enrollment

157 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • confirmed influenza A (H1N1, H3N2) or B infection by IFA or RT-PCR, with a compatible clinical illness
  • presented within 96 hours from symptom onset
  • age >/= 18 years

Exclusion criteria

  • lack of consent
  • suspected avian influenza
  • patients who have received antivirals against influenza prior to admission
  • suspected or confirmed oseltamivir resistance
  • pre-existing renal impairment, with creatinine clearance <40 ml/min
  • pre-existing hepatic failure
  • participation in a clinical study involving experimental medication in the past 4 weeks
  • pregnant women, or who are attempting to become pregnant, or who are breast feeding.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

157 participants in 2 patient groups

Non-intervention arm
No Intervention group
Description:
patients may receive oseltamivir 75 mg bd for 5 days, decided by the managing physicians
oseltamivir, higher dose
Active Comparator group
Description:
oseltamivir 150 mg bd for 5 days for patients presented within 96 hours from onset
Treatment:
Drug: Oseltamivir

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems